The authors concluded that although their results are preliminary, VASH1 density is a clinically relevant predictor of patient prognosis in UTUC and could be confirmed as a novel biomarker in external validation studies. This evidence concerns the gene VASH1 and renal pelvis/ureter urothelial carcinoma.